Here are updates on spine device company stock from five key companies.
NuVasive CEO Alexis V. Lukianov sold 7,452 shares of the company's stock on Monday, Jan. 12 at an average price of $49.69, for a total transaction value at $370,289, according to an Intercooler report. Zacks also gave the company a neutral rating, at three, according to a Stafford Daily report.
K2M reported preliminary fourth quarter results with revenue at $48.7 million to $49.3 million, up around 15 percent to 16 percent over the same period last year. The complex spine line reported 20 percent growth in the fourth quarter. Piper Jaffray assumed an Overweight rating for the company and a price target at $25, according to Street Insider.
LDR received an average broker rating score of three — a Hold — from Zacks. Two other analysts also rated the company as a Hold and the one-year consensus target price is at $37, according to a report from The Legacy.
Globus Medical received a Buy rating, according to WKRB News & Analysis, with the average price target reaching $26.91. Globus recently announced preliminary net sales increasing 9.1 percent in 2014 to $474 million.
Amedica shares dropped sharply on Jan. 12, with a high of 0.9452 and a low of 0.88, according to a Rock Hill Daily report. The company recently reported a "restructuring" that will reduce staff 28 percent, but the company hopes will strengthen operational efficiency and value proposition.